MA32590B1 - Derives de dioxa-bicyclo [3.2.1] octane-2,3,4-triol - Google Patents
Derives de dioxa-bicyclo [3.2.1] octane-2,3,4-triolInfo
- Publication number
- MA32590B1 MA32590B1 MA33651A MA33651A MA32590B1 MA 32590 B1 MA32590 B1 MA 32590B1 MA 33651 A MA33651 A MA 33651A MA 33651 A MA33651 A MA 33651A MA 32590 B1 MA32590 B1 MA 32590B1
- Authority
- MA
- Morocco
- Prior art keywords
- dioxa
- bicyclo
- octane
- triol derivatives
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention concerne des composés de formule (i) et leurs utilisations pour le traitement de maladies, d'affections et/ou de troubles médiés par des inhibiteurs des transporteurs sodium-glucose (en particulier, des inhibiteurs de sglt2). L'invention concerne des composés qui sont utiles pour la prévention et le traitement de l'obésité et de ses co-morbidités associées, en particulier un diabète de type ii (type 2).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9247008P | 2008-08-28 | 2008-08-28 | |
US22721209P | 2009-07-21 | 2009-07-21 | |
PCT/IB2009/053626 WO2010023594A1 (fr) | 2008-08-28 | 2009-08-17 | Dérivés de dioxa-bicyclo[3.2.1.]octane-2,3,4-triol |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32590B1 true MA32590B1 (fr) | 2011-08-01 |
Family
ID=41208284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33651A MA32590B1 (fr) | 2008-08-28 | 2011-02-28 | Derives de dioxa-bicyclo [3.2.1] octane-2,3,4-triol |
Country Status (47)
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011000637A (es) | 2008-07-15 | 2011-05-02 | Theracos Inc | Derivados deuretados de bencilbenceno y metodos de uso. |
ME02016B (me) | 2009-11-02 | 2015-05-20 | Pfizer | Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola |
EP2547679B1 (fr) | 2010-03-19 | 2015-11-04 | Pfizer Inc | Derivés de 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonane et leur utilisation en tant qu'antagonistes ou agonistes du récepteur de la ghréline |
CN102372722A (zh) | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用 |
WO2012041898A1 (fr) | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète |
AU2011322117B2 (en) | 2010-10-29 | 2015-01-22 | Pfizer Inc. | N1/N2-lactam acetyl-CoA carboxylase inhibitors |
US8980829B2 (en) * | 2011-02-18 | 2015-03-17 | Shanghai Yingli Science And Technology Co., Ltd | Aryl glycoside compound, preparation method and use thereof |
EP2680874A2 (fr) | 2011-03-04 | 2014-01-08 | Pfizer Inc | Peptides de type edn3 et utilisations associées |
CU24164B1 (es) | 2011-04-22 | 2016-03-31 | Pfizer | Inhibidores sustituidos de acetil-coa carboxilasa |
BR112013031032A2 (pt) | 2011-06-03 | 2016-11-29 | Boehringer Ingelheim Int | inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos |
JP2014517032A (ja) * | 2011-06-13 | 2014-07-17 | パナセア バイオテック リミテッド | 新規のsglt阻害剤 |
TWI510491B (zh) * | 2011-06-30 | 2015-12-01 | Shanghai Hengrui Pharm Co Ltd | C-芳基葡萄糖苷衍生物、其製備方法及其在醫藥上的應用 |
CA2841757A1 (fr) | 2011-07-15 | 2013-01-24 | Etzer Darout | Modulateurs de gpr 119 |
EP2734503B1 (fr) | 2011-07-22 | 2015-09-16 | Pfizer Inc. | Modulateurs des récepteurs de quinolinylglucagon |
JP6043355B2 (ja) | 2011-08-31 | 2016-12-14 | ファイザー・インク | ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
EP2755722B1 (fr) | 2011-09-13 | 2017-05-24 | Panacea Biotec Ltd. | Nouveaux inhibiteurs de sglt |
WO2013068439A1 (fr) | 2011-11-09 | 2013-05-16 | Intervet International B.V. | Composés 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazépine comme inhibiteurs de dgat1 |
WO2013068875A1 (fr) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | 2-thiopyrimidinones |
US9296745B2 (en) | 2012-04-06 | 2016-03-29 | Pfizer Inc. | Diacylglycerol acyltransferase 2 inhibitors |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
EP2852597B1 (fr) | 2012-05-04 | 2016-06-08 | Pfizer Inc | Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2 |
CN103570657A (zh) * | 2012-07-19 | 2014-02-12 | 天津药物研究院 | 一类含偕二甲基的苯基c-葡萄糖苷衍生物、其制备方法和用途 |
US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
JP2015529239A (ja) | 2012-09-20 | 2015-10-05 | ファイザー・インク | アルキル置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
CN103772449B (zh) * | 2012-10-26 | 2017-12-26 | 上海阳帆医药科技有限公司 | C‑芳基葡萄糖苷衍生物及其制备方法与用途 |
WO2014086099A1 (fr) * | 2012-12-05 | 2014-06-12 | 广东东阳光药业有限公司 | Dérivé glucopyranosylique, son procédé de préparation et son utilisation médicale |
WO2014091352A1 (fr) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1 |
EP3246324B1 (fr) * | 2012-12-17 | 2021-08-25 | Tianjin Institute of Pharmaceutical Research | Derive de phenyl-c-glucoside contenant une structure de desoxyglucose, son procede de preparation et ses utilisations |
US9403846B2 (en) | 2012-12-19 | 2016-08-02 | Pfizer Inc. | Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
CA2897678A1 (fr) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | Composes hexahydropyrano [3,4-d][1,3] thiazin-2-amine substitues par un heteroaryle |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
CN104045513A (zh) * | 2013-03-14 | 2014-09-17 | 爱康药业有限公司 | 4-取代-1-氯-2-(4-氟苄基)苯及其制备方法和作为中间体在制备抗ii型糖尿病药物中的应用 |
ES2740299T3 (es) | 2013-03-14 | 2020-02-05 | Msd Int Gmbh | Métodos para preparar inhibidores de SGLT2 |
ES2959444T3 (es) | 2013-04-04 | 2024-02-26 | Boehringer Ingelheim Vetmedica Gmbh | Tratamiento de trastornos metabólicos en animales equinos |
WO2014187365A1 (fr) * | 2013-05-24 | 2014-11-27 | 四川海思科制药有限公司 | Dérivés oxabicyclo, procédé de préparation et utilisation de ceux-ci |
WO2015027963A1 (fr) * | 2013-09-02 | 2015-03-05 | 四川海思科制药有限公司 | Dérivé à noyau aromatique, composition pharmaceutique et utilisation associée |
EP2895490B1 (fr) * | 2013-09-27 | 2016-10-19 | Sunshine Lake Pharma Co., Ltd. | Dérivés de glucopyranosyl et leurs utilisations en médecine |
ES2665153T3 (es) | 2013-10-09 | 2018-04-24 | Pfizer Inc. | Antagonistas del receptor EP3 de prostaglandina |
CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
EP4285995A3 (fr) | 2013-12-17 | 2024-02-28 | Boehringer Ingelheim Vetmedica GmbH | Un inhibiteur de sglt-2 pour le traitement des troubles métaboliques chez les félins |
KR20220097538A (ko) | 2014-01-23 | 2022-07-07 | 베링거잉겔하임베트메디카게엠베하 | 개과 동물에서 대사 장애의 치료 |
CN106103425A (zh) | 2014-03-17 | 2016-11-09 | 辉瑞公司 | 用于治疗代谢及相关病症的二酰甘油酰基转移酶2抑制剂 |
NZ723781A (en) * | 2014-04-01 | 2022-09-30 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
ES2718552T3 (es) | 2014-04-04 | 2019-07-02 | Pfizer | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de IRAK4 |
AP2016009493A0 (en) | 2014-04-10 | 2016-10-31 | Pfizer | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES |
EP3145934B1 (fr) | 2014-05-19 | 2020-11-11 | Pfizer Inc | Comoses substitues de dioxabicyclo[3.2.1]octane-2,3-diol en tant qu'agents de ciblage d'asgpr |
CN104031098A (zh) * | 2014-06-21 | 2014-09-10 | 李友香 | 降糖药物 |
CN104017031A (zh) * | 2014-06-21 | 2014-09-03 | 李友香 | 降血糖药物和组合物 |
US10555958B2 (en) | 2014-09-25 | 2020-02-11 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
CN105461762B (zh) * | 2014-09-27 | 2018-12-04 | 广东东阳光药业有限公司 | 吡喃葡萄糖基衍生物及其在医药上的应用 |
EP3202772B1 (fr) * | 2014-09-30 | 2020-10-28 | Jiangsu Hengrui Medicine Co. Ltd. | Cristal du complexe l-proline/inhibiteur du cotransporteur sodium-glucose de type 2 |
WO2016077126A1 (fr) | 2014-11-10 | 2016-05-19 | Merck Sharp & Dohme Corp. | Inhibiteurs de sglt-2 pour le traitement de troubles métaboliques chez des patients présentant une insuffisance rénale ou une maladie rénale chronique |
WO2016092413A1 (fr) | 2014-12-10 | 2016-06-16 | Pfizer Inc. | Composés indoliques et indazoliques qui activent l'ampk |
JP2017538769A (ja) | 2014-12-22 | 2017-12-28 | ファイザー・インク | プロスタグランジンep3受容体の拮抗薬 |
WO2016178113A1 (fr) | 2015-05-05 | 2016-11-10 | Pfizer Inc. | 2-thiopyrimidinones |
WO2016189463A1 (fr) * | 2015-05-25 | 2016-12-01 | Sun Pharmaceutical Industries Limited | Co-cristaux d'ertuglifozine et procédé pour les préparer |
CA2987179C (fr) | 2015-05-29 | 2020-08-25 | Pfizer Inc. | Composes heterocycliques comme inhibiteurs de l'enzyme vanine-1 |
WO2016203347A1 (fr) | 2015-06-17 | 2016-12-22 | Pfizer Inc. | Composés tricycliques et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase |
WO2016203335A1 (fr) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Nouvelles pyrido [2,3-b] pyrazinones utilisées en tant qu'inhibiteurs de bromodomaines de la famille bet |
US20180230127A1 (en) | 2015-08-13 | 2018-08-16 | Pfizer Inc. | Bicyclic-Fused Heteroaryl Or Aryl Compounds |
EP3341024A1 (fr) | 2015-08-27 | 2018-07-04 | Boehringer Ingelheim Vetmedica GmbH | Compositions pharmaceutiques liquides comprenant des inhibiteurs de sglt-2 |
MX2018002402A (es) | 2015-08-27 | 2018-04-11 | Pfizer | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). |
WO2017037567A1 (fr) | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Régulateurs de la frataxine |
WO2017051276A1 (fr) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(2-amino-6,6-disubstitués-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl)-1,3-thiazol-4-yl]amides |
WO2017051294A1 (fr) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-diméthyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides utiles comme inhibiteurs de bace |
JP2018531924A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | テトラヒドロピラノ[3,4−d][1,3]オキサジン誘導体、およびbace阻害剤としてのその使用 |
SG11201804363UA (en) | 2015-12-29 | 2018-07-30 | Pfizer | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
HUE051212T2 (hu) | 2016-01-04 | 2021-03-01 | Jeil Pharmaceutical Co Ltd | Kondenzált fenilgyûrût tartalmazó C-glükozid származék vagy annak gyógyászatilag elfogadható sója, eljárás annak elõállítására és azt tartalmazó gyógyászati kompozíció |
CN105646603A (zh) * | 2016-03-01 | 2016-06-08 | 孙霖 | 埃格列净晶型a及制备方法 |
CN105646604A (zh) * | 2016-03-01 | 2016-06-08 | 孙霖 | 埃格列净晶型b及制备方法 |
WO2017155841A1 (fr) * | 2016-03-11 | 2017-09-14 | Merck Sharp & Dohme Corp. | Procédé de traitement ou de réduction du risque d'événements cardiovasculaires et de maladies associées au moyen d'inhibiteur de sglt-2 |
WO2018011681A1 (fr) | 2016-07-14 | 2018-01-18 | Pfizer Inc. | Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1 |
WO2018011721A1 (fr) * | 2016-07-15 | 2018-01-18 | Granules India Limited | Nouvelles formes polymorphes de ((1s,2s,3s,4r,5s))-2,3,4-(tris-benzyloxy)-5-(4-chloro-3-(4-éthoxy-benzyl)phényl)-6,8-dioxa-bicyclo[3.2.1]oct-1-yl-méthanol |
AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
JP2019531320A (ja) | 2016-10-19 | 2019-10-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ssao/vap−1阻害剤とsglt2阻害剤とを含む組合せ、その使用 |
CN107382952B (zh) * | 2017-07-13 | 2020-02-28 | 杭州科巢生物科技有限公司 | 埃格列净的制备方法及其中间体 |
CN107898764A (zh) * | 2017-12-12 | 2018-04-13 | 威海贯标信息科技有限公司 | 一种埃格列净组合物 |
WO2019133445A1 (fr) | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles utilisés en tant qu'inhibiteurs de vanin-1 |
CN107857768A (zh) * | 2018-01-04 | 2018-03-30 | 威海贯标信息科技有限公司 | 一种埃格列净新晶型 |
WO2019169988A1 (fr) * | 2018-03-06 | 2019-09-12 | 广东东阳光药业有限公司 | Formes cristallines d'ertugliflozine et procédé de préparation associé |
US20210113561A1 (en) | 2018-04-17 | 2021-04-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2019202149A1 (fr) | 2018-04-19 | 2019-10-24 | Université Catholique de Louvain | Inhibiteurs de sglt2 pour le traitement de la neutropénie |
WO2020001812A1 (fr) | 2018-06-25 | 2020-01-02 | Pharmathen S.A. | Nouveau procédé de préparation d'inhibiteurs de sglt-2 |
WO2020026273A1 (fr) * | 2018-07-31 | 2020-02-06 | Msn Laboratories Private Limited, R&D Center | Formes solides de base libre d'ertugliflozine et dispersions à l'état solide comprenant de l'acide ertugliflozin l-pyroglutamique |
WO2020039394A1 (fr) | 2018-08-24 | 2020-02-27 | Novartis Ag | Nouvelles combinaisons de médicaments |
KR102614808B1 (ko) | 2018-08-31 | 2023-12-19 | 화이자 인코포레이티드 | Nash/nafld 및 관련 질환의 치료를 위한 조합물 |
WO2020102575A1 (fr) | 2018-11-16 | 2020-05-22 | Inception Ibd, Inc. | Aminothiazoles hétérocycliques et leurs utilisations |
EP3972596A1 (fr) | 2019-05-20 | 2022-03-30 | Pfizer Inc. | Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinées à être utilisées dans le traitement de la nash/nafld et de maladies associées |
WO2020261144A1 (fr) | 2019-06-28 | 2020-12-30 | Pfizer Inc. | Dérivés de 5-(thiophén-2-yl) -1h-tétrazole utilisés en tant qu'inhibiteurs de bckdk utiles pour le traitement de diverses maladies |
TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
TW202116746A (zh) * | 2019-07-10 | 2021-05-01 | 大陸商廣東東陽光藥業有限公司 | 吡喃葡萄糖基衍生物及其用途 |
TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶2 抑制劑 |
US11759474B2 (en) | 2019-11-28 | 2023-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Use of SGLT-2 inhibitors in the drying-off of non-human mammals |
CN113330017B (zh) * | 2019-12-19 | 2023-01-31 | 上海研健新药研发有限公司 | 一种SGLTs抑制剂的纯化方法及其应用 |
AU2021222297A1 (en) | 2020-02-17 | 2022-08-04 | Boehringer Ingelheim Vetmedica Gmbh | Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines |
JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
JP2023523596A (ja) | 2020-04-22 | 2023-06-06 | バイエル アクチェンゲゼルシャフト | 心血管疾患および/または腎疾患を治療および/または予防するためのフィネレノンとsglt2阻害剤の組み合わせ |
CA3186348A1 (fr) | 2020-06-09 | 2021-12-16 | Pfizer Inc. | Composes spiro en tant qu'antagonistes du recepteur de la melanocortine 4 et leurs utilisations |
WO2021260498A1 (fr) * | 2020-06-22 | 2021-12-30 | Aurobindo Pharma Limited | Procédé de purification amélioré pour la préparation de co-cristal d'acide ertugliflozine et d'ertugliflozin l-pyroglutamique |
CN114195748B (zh) * | 2020-09-17 | 2023-11-14 | 上海森辉医药有限公司 | 一种钠-葡萄糖协同转运蛋白2抑制剂的制备方法 |
WO2023006718A1 (fr) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de maladies cardiaques chez des mammifères non humains à l'exclusion de félins, en particulier des canidés |
CA3224673A1 (fr) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Utilisation d'inhibiteurs de sglt-2 pour la prevention et/ou le traitement de maladies renales chez des mammiferes non humains |
EP4376819A1 (fr) | 2021-07-28 | 2024-06-05 | Boehringer Ingelheim Vetmedica GmbH | Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de l'hypertension chez des mammifères non humains |
WO2023026180A1 (fr) | 2021-08-26 | 2023-03-02 | Pfizer Inc. | Forme amorphe de (s)-2-(5-((3-éthoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tétrahydrofuran-3-yl)pyrimidine-5-carboxamide |
KR20230060921A (ko) | 2021-10-28 | 2023-05-08 | 유니셀랩 주식회사 | 에르투글리플로진의 신규 전구체 |
IL312296A (en) | 2021-12-01 | 2024-06-01 | Pfizer | 3-PHENYL-1-BENZOTHIOPEN-2-CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF BRANCHED ALPHA KETO ACID DEHYDROGENSIS KINASE FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART |
WO2023105387A1 (fr) | 2021-12-06 | 2023-06-15 | Pfizer Inc. | Antagonistes du récepteur 4 de la mélanocortine et leurs utilisations |
WO2023169456A1 (fr) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Agonistes hétérocycliques de glp-1 |
WO2023198140A1 (fr) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Agonistes hétérocycliques de glp-1 |
US20230381101A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
WO2024075051A1 (fr) | 2022-10-07 | 2024-04-11 | Pfizer Inc. | Inhibiteurs et/ou agents de dégradation de hsd17b13 |
WO2024084360A1 (fr) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Modificateurs de la proteine 3 contenant le domaine phospholipase de type patatine (pnpla3) |
WO2024118524A1 (fr) | 2022-11-28 | 2024-06-06 | Cerevel Therapeutics, Llc | Composés d'azaindole et leur utilisation en tant qu'inhibiteurs de phosphodiestérase |
WO2024125602A1 (fr) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Sels et formes solides d'un composé ayant une activité agoniste de glp-1 |
WO2024127297A1 (fr) | 2022-12-16 | 2024-06-20 | Pfizer Inc. | Inhibiteurs et/ou agents de dégradation contenant du 3-fluoro-4-hydroxybenzmide et leurs utilisations |
Family Cites Families (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US486299A (en) * | 1892-11-15 | John k | ||
US247705A (en) * | 1881-09-27 | William a | ||
US560230A (en) * | 1896-05-19 | powers | ||
US838442A (en) * | 1906-05-31 | 1906-12-11 | Oscar Mietens | Compressed-air railway-train brake. |
FR1499439A (fr) * | 1966-09-16 | 1967-10-27 | Electrochimie Soc | Nouveau polyol et procédé pour sa préparation |
JPS5373598A (en) * | 1976-12-11 | 1978-06-30 | Teikoku Chem Ind Corp Ltd | Saccharide derivatives and process for thir preparation |
JPS5911600B2 (ja) * | 1981-04-30 | 1984-03-16 | 理化学研究所 | 3−アジド−1,6−アンヒドロ−3−デオキシ−2,4−ジ−O−ベンジル−β−D−グルコピラノ−ス及びその製造法 |
NZ214774A (en) | 1986-01-08 | 1989-10-27 | Nz Scientific & Ind Res | Herbicidal and/or plant growth regulatory compositions based on 1,6-anhydro-beta-hexopyranose derivatives and certain of these derivatives |
US5041541A (en) | 1988-05-05 | 1991-08-20 | The Procter & Gamble Company | Functional sugar substituted with reduced calories |
CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
CA2079544A1 (fr) | 1991-10-04 | 1993-04-05 | Adam Weislaw Mazur | Composes permettant de faire baisser le taux de cholesterol |
DE4400464A1 (de) * | 1994-01-11 | 1995-07-13 | Bayer Ag | Endoparasitizide Mittel |
EP0850948B1 (fr) | 1996-12-26 | 2002-04-24 | Tanabe Seiyaku Co., Ltd. | Dérivés de propiophénone et un procédé pour leur préparation |
US6486299B1 (en) | 1998-09-28 | 2002-11-26 | Curagen Corporation | Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity |
US6069238A (en) | 1998-09-30 | 2000-05-30 | Eli Lilly And Company | Spirocyclic C-glycosides |
AU782330B2 (en) | 1999-08-31 | 2005-07-21 | Kissei Pharmaceutical Co. Ltd. | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
WO2001042469A1 (fr) | 1999-12-10 | 2001-06-14 | Lexicon Genetics Incorporated | Nouvelle proteine transporteuse humaine et polynucleotides codant celle-ci |
US6627611B2 (en) | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
DE10006887A1 (de) | 2000-02-16 | 2001-09-06 | Hermann Koepsell | Verbindungen, die die Aktivität oder die Konzentration des Regulatorproteins RS1 verändern |
DE10008128A1 (de) | 2000-02-22 | 2001-08-23 | Bayer Ag | Endoparasitizide Mittel |
KR100660738B1 (ko) | 2000-03-17 | 2006-12-22 | 깃세이 야쿠힌 고교 가부시키가이샤 | 글루코피라노실록시 벤질벤젠 유도체, 그것을 함유하는의약조성물 및 그 제조중간체 |
US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
JP3798375B2 (ja) | 2000-09-29 | 2006-07-19 | キッセイ薬品工業株式会社 | グルコピラノシルオキシベンジルベンゼン誘導体およびそれを含有する医薬組成物 |
WO2002036602A1 (fr) | 2000-11-02 | 2002-05-10 | Ajinomoto Co., Inc. | Nouveaux derives du pyrazole et remedes au diabete contenant ces derniers |
CA2429833A1 (fr) | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions |
US20020081678A1 (en) | 2000-12-11 | 2002-06-27 | Gennady Merkulov | Isolated nucleic acid molecules encoding human transporter proteins, and uses thereof |
ATE431830T1 (de) | 2000-12-28 | 2009-06-15 | Kissei Pharmaceutical | Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln |
WO2002053738A1 (fr) | 2000-12-28 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Nouvelles proteines et adn correspondant |
TWI255817B (en) | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
ES2319263T3 (es) | 2001-02-26 | 2009-05-06 | Kissei Pharmaceutical Co., Ltd. | Derivados de glucopiranosilooxipirazol y su utilizacion como medicamentos. |
US7294618B2 (en) | 2001-02-27 | 2007-11-13 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and medicinal use thereof |
US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
WO2002081654A2 (fr) | 2001-03-27 | 2002-10-17 | Pe Corporation (Ny) | Proteines transporteur humaines isolees, molecules d'acide nucleique codant ces proteines transporteur humaines et utilisations de ces dernieres |
US6838442B2 (en) | 2001-04-04 | 2005-01-04 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators |
ATE423559T1 (de) | 2001-04-04 | 2009-03-15 | Ortho Mcneil Janssen Pharm | Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren |
US20030054453A1 (en) | 2001-04-10 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | 68723, sodium/glucose cotransporter family members and uses therefor |
JP2004536047A (ja) | 2001-04-11 | 2004-12-02 | ブリストル−マイヤーズ スクイブ カンパニー | 糖尿病処置用c−アリールグルコシドのアミノ酸複合体および方法 |
WO2002088157A1 (fr) | 2001-04-27 | 2002-11-07 | Ajinomoto Co., Inc. | Derives pyrazolyl-o-glycoside n-substitues et medicament contre le diabete en contenant |
EP1400529A4 (fr) | 2001-05-30 | 2007-12-19 | Kissei Pharmaceutical | Derive de glucopyranosyloxypyrazole, composition medicinale contenant celui-ci, et utilisation medicinale et intermediaire de celui-ci |
US7271153B2 (en) | 2001-06-20 | 2007-09-18 | Kissei Pharmaceutical Co., Ltd. | Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor |
JP4115105B2 (ja) | 2001-07-02 | 2008-07-09 | 協和醗酵工業株式会社 | ピラゾール誘導体 |
US7082091B2 (en) * | 2001-07-31 | 2006-07-25 | Ricoh Company, Ltd. | Information reproducing method judging a multivalued level of a present cell by referring to judged multivalued levels of a preceding cell and an ensuing cell |
US7371730B2 (en) | 2002-03-22 | 2008-05-13 | Kissei Pharmaceutical Co., Ltd. | Crystals of glucopyranosyloxybenzyl benzene derivative |
US20070059356A1 (en) | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
DE10225844A1 (de) | 2002-06-04 | 2003-12-18 | Lang Florian | sgk und nedd als diagnostische und therapeutische targets |
DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
TWI254635B (en) | 2002-08-05 | 2006-05-11 | Yamanouchi Pharma Co Ltd | Azulene derivative and salt thereof |
EP1544208B1 (fr) | 2002-08-08 | 2010-05-26 | Kissei Pharmaceutical Co., Ltd. | Derive de pyrazole, composition medicinale contenant ce derive, utilisation therapeutique de ceux-ci et intermediaire pour la production de cette composition |
DE10237085A1 (de) | 2002-08-09 | 2004-02-19 | Bioagency Ag | Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen |
BR0310006A (pt) | 2002-08-09 | 2005-02-15 | Taisho Pharmaceutical Co Ltd | Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos |
JP2004137245A (ja) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
US20060063711A1 (en) | 2002-10-29 | 2006-03-23 | Keiji Iwamoto | Use of sglt homolog |
JPWO2004050122A1 (ja) | 2002-12-04 | 2006-03-30 | キッセイ薬品工業株式会社 | 高血糖症に起因する疾患の予防又は治療剤 |
JP4651934B2 (ja) | 2002-12-04 | 2011-03-16 | キッセイ薬品工業株式会社 | ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途 |
DE10258008B4 (de) | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
EP1577317A4 (fr) | 2002-12-25 | 2007-05-09 | Kissei Pharmaceutical | Derives heterocycliques contenant de l'azote, compositions medicinales contenant lesdits derives et utilisation medicale desdits derives |
CN101260130A (zh) | 2003-01-03 | 2008-09-10 | 布里斯托尔-迈尔斯斯奎布公司 | 制备c-芳基葡糖苷sglt2抑制剂的方法 |
WO2004081181A2 (fr) | 2003-03-07 | 2004-09-23 | Threshold Pharmaceuticals, Inc. | Procede permettant de determiner la susceptibilite d'une tumeur au traitement par agent neoplasique |
PL1980560T3 (pl) | 2003-03-14 | 2011-11-30 | Astellas Pharma Inc | Pochodne C-glikozydowe do leczenia cukrzycy |
JP2004300102A (ja) | 2003-03-31 | 2004-10-28 | Kissei Pharmaceut Co Ltd | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
CN1761676A (zh) | 2003-04-01 | 2006-04-19 | 大正制药株式会社 | 杂芳基5-硫代-β-D-吡喃葡糖苷衍生物及含有该衍生物的糖尿病治疗药 |
JPWO2004089967A1 (ja) | 2003-04-01 | 2006-07-06 | 大正製薬株式会社 | ヘテロアリール5−チオ−β−D−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬 |
AU2003902263A0 (en) | 2003-05-12 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Monosaccharide compounds |
JPWO2004106352A1 (ja) | 2003-05-29 | 2006-07-20 | 大正製薬株式会社 | アルドヘキソピラノース中間体の製造法 |
JP2004359630A (ja) | 2003-06-06 | 2004-12-24 | Yamanouchi Pharmaceut Co Ltd | ジフルオロジフェニルメタン誘導体及びその塩 |
US7576064B2 (en) | 2003-06-20 | 2009-08-18 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, drug composition containing the same and production intermediate therefor |
AR045173A1 (es) | 2003-08-01 | 2005-10-19 | Tanabe Seiyaku Co | Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio |
UA86042C2 (en) | 2003-08-01 | 2009-03-25 | Янссен Фармацевтика Н.В. | Substituted indazole-o-glucosides |
US7375090B2 (en) | 2003-08-26 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof |
US7371732B2 (en) | 2003-12-22 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture |
JP2005247834A (ja) | 2004-02-04 | 2005-09-15 | Taisho Pharmaceut Co Ltd | ナトリウム依存性グルコース供輸送体2の活性阻害剤 |
EP1724278B1 (fr) | 2004-03-04 | 2014-05-07 | Kissei Pharmaceutical Co., Ltd. | Derives de noyaux fondus azotes, compositions therapeutiques contenant ces derives et utilisation de ceux-ci en tant que medicaments |
CN1934103B (zh) | 2004-03-04 | 2011-06-01 | 橘生药品工业株式会社 | 稠杂环衍生物,包含稠杂环衍生物的药物组合物及其医药用途 |
NZ549219A (en) | 2004-03-04 | 2010-08-27 | Kissei Pharmaceutical | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
CN103435581B (zh) | 2004-03-16 | 2015-08-19 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
DE102004012676A1 (de) * | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
JPWO2005095429A1 (ja) | 2004-03-31 | 2008-02-21 | キッセイ薬品工業株式会社 | フェノール誘導体、それを含有する医薬組成物及びその医薬用途 |
JPWO2005095372A1 (ja) | 2004-03-31 | 2008-02-21 | キッセイ薬品工業株式会社 | ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途 |
TW200602335A (en) | 2004-03-31 | 2006-01-16 | Kissei Pharmaceutical | Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof |
DE102004028241B4 (de) | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
US20070293690A1 (en) | 2004-07-08 | 2007-12-20 | Hiroshi Tomiyama | Process for Production of Azulene Derivatives and Intermediates for the Synthesis of the Same |
DE102004034690A1 (de) | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
CA2572793C (fr) | 2004-07-21 | 2015-11-03 | Kissei Pharmaceutical Co., Ltd. | Inhibiteur de la progression d'une maladie attribuee a une accumulation anormale de corps gras dans le foie |
TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
CA2574451A1 (fr) | 2004-07-27 | 2006-02-02 | Boehringer Ingelheim International Gmbh | Cyclenes substitues par d-glucopyranosyle-phenyle, medicaments contenant lesdits composes, leur utilisation et procede de production correspondant |
WO2006018150A1 (fr) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | Cycles a substitution d-xylopyranosyl-phenyle, medicaments contenant ces composes, leur utilisation, et leur procede de production |
AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
JP2006117651A (ja) | 2004-09-27 | 2006-05-11 | Taisho Pharmaceut Co Ltd | Sglt2の活性阻害剤 |
US20080139484A1 (en) | 2004-09-29 | 2008-06-12 | Kissei Pharmaceutical Co., Ltd. | 1(Beta-D-Glycopyranosyl)-3-Substituted Nitrogenous Heterocyclic Compound, Medicinal Composition Containing the Same, and Medicinal Use Thereof |
DE102004048388A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US7750145B2 (en) | 2004-11-18 | 2010-07-06 | Kissei Pharmaceutical Co., Ltd. | 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same |
JP2008007405A (ja) | 2004-12-07 | 2008-01-17 | Takeda Chem Ind Ltd | カルボキサミド誘導体 |
ES2314743T3 (es) | 2004-12-16 | 2009-03-16 | Boehringer Ingelheim International Gmbh | Derivados de benceno sustituidos con glucopiranosilo, medicamentos que contienen a este tipo de compuestos, su uso y procedimiento para su fabricacion. |
TW200637839A (en) | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
AR053329A1 (es) | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
ES2358342T3 (es) | 2005-02-15 | 2011-05-09 | Kissei Pharmaceutical Co., Ltd. | Compuesto 1-sustituido-7-(beta-d-glicopiranosiloxi)(aza)indol y composición farmacéutica comprendiendo el mismo. |
WO2006089872A1 (fr) | 2005-02-23 | 2006-08-31 | Boehringer Ingelheim International Gmbh | Derives d'(hetero)arylethynyl-benzyd-benzene a substitution glucopyranosyle et leur utilisation en tant que cotransporteur 2 de glucose dependant de sodium (sglt2) |
EP1874787B1 (fr) | 2005-04-15 | 2009-12-30 | Boehringer Ingelheim International GmbH | Derives de glucopyranosyl-substitue (heteroaryloxy-benzyl)-benzene utilises comme inhibiteurs de sglt |
CA2604333A1 (fr) | 2005-04-15 | 2006-10-19 | Cenix Bioscience Gmbh | Genes marqueurs humains et agents de diagnostic, de traitement et de prophylaxie des troubles cardio-vasculaires et de l'atherosclerose |
JPWO2006115137A1 (ja) | 2005-04-22 | 2008-12-18 | キッセイ薬品工業株式会社 | 2−アミノベンズイミダゾール誘導体及びその医薬用途 |
WO2006119038A1 (fr) | 2005-04-29 | 2006-11-09 | Naturegen, Inc. | Compositions et procedes pour controler l'assimilation de glucose |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
WO2007000445A1 (fr) | 2005-06-29 | 2007-01-04 | Boehringer Ingelheim International Gmbh | Derives de benzyle-benzene a substitution glucopyranosyle, medicaments contenant de tels composes, utilisation et production de ces derniers |
TW200726755A (en) | 2005-07-07 | 2007-07-16 | Astellas Pharma Inc | A crystalline choline salt of an azulene derivative |
WO2007014894A2 (fr) | 2005-07-27 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Derives de ((hetero)cycloalkylethynyl-benzyl)-benzene glucopyranosyl-substitutes, medicaments contenant ces composes, leur utilisation, et procede pour les produire |
WO2007019526A2 (fr) | 2005-08-05 | 2007-02-15 | Naturegen, Inc. | Compositions et procedes pour controler l'apport de glucose et de lipide par des aliments |
EP1924571B1 (fr) | 2005-08-30 | 2010-10-13 | Boehringer Ingelheim International Gmbh | Derives benzyl-benzene substitues par glucopyranosyle, medicaments contenant ces composes, leur utilisation et leur procede de preparation |
RU2008113050A (ru) | 2005-09-08 | 2009-10-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-ЭТИНИЛБЕНЗИН)-БЕНЗОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ |
US20070099237A1 (en) | 2005-10-31 | 2007-05-03 | The Regents Of The University Of Michigan | Reaction co-crystallization of molecular complexes or co-crystals |
TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
JP2009167103A (ja) | 2006-05-02 | 2009-07-30 | Taisho Pharmaceutical Co Ltd | ピラゾリル5−チオグリコシド化合物 |
JP2009167104A (ja) | 2006-05-02 | 2009-07-30 | Taisho Pharmaceutical Co Ltd | フェニル5−チオグリコシド化合物 |
PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
JP5230613B2 (ja) * | 2006-05-23 | 2013-07-10 | テラコス・インコーポレイテッド | グルコース輸送体阻害剤およびその使用方法 |
DE102006028862A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
JP5152519B2 (ja) | 2006-06-29 | 2013-02-27 | 大正製薬株式会社 | C−フェニル1−チオグルシト−ル化合物 |
TWI403516B (zh) * | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
TWI432446B (zh) | 2006-07-27 | 2014-04-01 | Chugai Pharmaceutical Co Ltd | 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用 |
TWI418556B (zh) | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
JP2008050353A (ja) | 2006-07-27 | 2008-03-06 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
US20080027014A1 (en) | 2006-07-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Novel SGLT inhibitors |
TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
CN101121148B (zh) | 2006-08-08 | 2010-05-12 | 中国科学院大连化学物理研究所 | 一种含分子筛的流化反应催化剂直接成型方法 |
MX2009001413A (es) * | 2006-08-09 | 2009-02-17 | Dow Global Technologies Inc | Multi-segmento de composiciones de polimero expandible las cuales se expanden en una dreccion controlable. |
US8039441B2 (en) | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
CA2664095A1 (fr) | 2006-09-21 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Derives du difluorobenzyl-benzene substitues par glucopyranosyle, medicament contenant ces composes, leur utilisation et procede pour leur fabrication |
EP2072522A4 (fr) | 2006-10-13 | 2010-01-06 | Chugai Pharmaceutical Co Ltd | Dérivé de spirocétal de thioglucose et utilisation de celui-ci comme agent thérapeutique pour le diabète |
DE102006048728A1 (de) | 2006-10-16 | 2008-04-17 | Merck Patent Gmbh | 3-Amino-imidazo{1,2-a]pyridinderivate |
US8283326B2 (en) | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
WO2008055870A1 (fr) | 2006-11-06 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Dérivés de benzyl-benzonitrile substitués par glucopyranosyle, médicaments contenant de tels composés, leur utilisation et procédé pour leur fabrication |
WO2008115574A1 (fr) | 2007-03-21 | 2008-09-25 | Reliant Pharmaceuticals, Inc. | Antagoniste cb1 et agent dyslipidémique et/ou régulateur métabolique et procédés de préparation et d'utilisation correspondants |
TW200904454A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
DK2183263T3 (da) | 2007-07-26 | 2012-01-30 | Lexicon Pharmaceuticals Inc | Fremgangsmåder og forbindelser anvendelige til fremstilling af natriumglucose-cotransportør-2-inhibitorer |
CL2008002425A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta. |
RU2497526C2 (ru) | 2007-08-23 | 2013-11-10 | Теракос, Инк. | Производные бензилбензола и способы их применения |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
CN101503399B (zh) * | 2008-02-04 | 2012-06-27 | 白鹭医药技术(上海)有限公司 | C-芳基葡萄糖苷sglt2抑制剂 |
-
2009
- 2009-08-17 BR BRPI0918841A patent/BRPI0918841B8/pt active IP Right Grant
- 2009-08-17 GE GEAP200912121A patent/GEP20135803B/en unknown
- 2009-08-17 CN CN200980135661.2A patent/CN102149717B/zh active Active
- 2009-08-17 WO PCT/IB2009/053626 patent/WO2010023594A1/fr active Application Filing
- 2009-08-17 CA CA2733795A patent/CA2733795C/fr active Active
- 2009-08-17 EP EP09786960A patent/EP2334687B9/fr active Active
- 2009-08-17 PE PE2011000205A patent/PE20110288A1/es active IP Right Grant
- 2009-08-17 AU AU2009286380A patent/AU2009286380B2/en active Active
- 2009-08-17 MY MYPI2011000903A patent/MY155418A/en unknown
- 2009-08-17 AP AP2011005616A patent/AP2728A/xx active
- 2009-08-17 PL PL09786960T patent/PL2334687T3/pl unknown
- 2009-08-17 ME MEP-2011-45A patent/ME01285A/me unknown
- 2009-08-17 MX MX2011002166A patent/MX2011002166A/es active IP Right Grant
- 2009-08-17 PT PT09786960T patent/PT2334687E/pt unknown
- 2009-08-17 JP JP2011524489A patent/JP4825322B1/ja active Active
- 2009-08-17 CN CN201310128399.7A patent/CN103497199B/zh active Active
- 2009-08-17 KR KR1020117006928A patent/KR101338540B1/ko active IP Right Grant
- 2009-08-17 DK DK09786960.6T patent/DK2334687T5/da active
- 2009-08-17 AT AT09786960T patent/ATE540040T1/de active
- 2009-08-17 NZ NZ591027A patent/NZ591027A/xx unknown
- 2009-08-17 RS RS20120084A patent/RS52236B/en unknown
- 2009-08-17 SI SI200930161T patent/SI2334687T1/sl unknown
- 2009-08-17 KR KR1020137025842A patent/KR101446454B1/ko active IP Right Grant
- 2009-08-17 ES ES09786960T patent/ES2380408T3/es active Active
- 2009-08-17 EA EA201100266A patent/EA018492B1/ru active Protection Beyond IP Right Term
- 2009-08-24 US US12/546,306 patent/US8080580B2/en active Active
- 2009-08-26 HN HN2009001652A patent/HN2009001652A/es unknown
- 2009-08-26 AR ARP090103280A patent/AR073138A1/es active IP Right Grant
- 2009-08-26 UY UY0001032073A patent/UY32073A/es active IP Right Grant
- 2009-08-27 PA PA20098840801A patent/PA8840801A1/es unknown
- 2009-08-27 TW TW098128894A patent/TWI387598B/zh active
-
2011
- 2011-02-09 CR CR20110077A patent/CR20110077A/es unknown
- 2011-02-14 IL IL211226A patent/IL211226A/en active Protection Beyond IP Right Term
- 2011-02-17 SV SV2011003842A patent/SV2011003842A/es unknown
- 2011-02-18 ZA ZA2011/01341A patent/ZA201101341B/en unknown
- 2011-02-21 DO DO2011000058A patent/DOP2011000058A/es unknown
- 2011-02-23 CL CL2011000394A patent/CL2011000394A1/es unknown
- 2011-02-23 CO CO11022222A patent/CO6341636A2/es active IP Right Grant
- 2011-02-24 NI NI201100043A patent/NI201100043A/es unknown
- 2011-02-28 EC EC2011010854A patent/ECSP11010854A/es unknown
- 2011-02-28 MA MA33651A patent/MA32590B1/fr unknown
- 2011-10-13 HK HK11110890.7A patent/HK1156616A1/xx unknown
-
2012
- 2012-02-01 HR HR20120104T patent/HRP20120104T1/hr unknown
- 2012-03-15 CY CY20121100280T patent/CY1112497T1/el unknown
-
2014
- 2014-07-08 HK HK14106953.6A patent/HK1193606A1/xx unknown
-
2015
- 2015-01-19 IL IL236804A patent/IL236804B/en active IP Right Grant
-
2018
- 2018-06-26 NO NO2018019C patent/NO2018019I2/no unknown
- 2018-06-27 NL NL300943C patent/NL300943I2/nl unknown
- 2018-07-13 HU HUS1800031C patent/HUS1800031I1/hu unknown
- 2018-08-21 LT LTPA2018510C patent/LTC2334687I2/lt unknown
- 2018-08-24 FR FR18C1036C patent/FR18C1036I2/fr active Active
- 2018-09-03 CY CY2018024C patent/CY2018024I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32590B1 (fr) | Derives de dioxa-bicyclo [3.2.1] octane-2,3,4-triol | |
CY1119810T1 (el) | Παραγωγα(2s,3r,4r,5s,6r)-2-(4-χλωρο-3-βενζυλφαινυλ)-6-(υδροξυμεθυλ)τετραϋδρο-2h-πυραν-3,4,5-τριολης για χρηση στη θεραπεια του διαβητη | |
TW200738724A (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
CR9347A (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
GEP20135793B (en) | Heteroaryls amide derivatives and their use as glucokinase activators | |
MA32467B1 (fr) | Derives de piperidinyle agonistes de gpcr | |
MY151246A (en) | Benzofuranyl derivatives | |
EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
WO2010111406A3 (fr) | Composés et leurs utilisations thérapeutiques | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
UA107783C2 (en) | Isoindoline compounds for use in treating cancer | |
DK2164331T3 (da) | Borholdige små molekyler | |
CR20120289A (es) | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol | |
JO2645B1 (en) | Vehicles | |
ATE542795T1 (de) | Benzylpiperazinderivate als motilin- rezeptorantagonisten | |
EA201190140A1 (ru) | Производные циклопропиламида, направленно действующие на гистаминовый н3-рецептор | |
MA32945B1 (fr) | Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique | |
CR10036A (es) | Procedimientos para la preparación de derivados de ciclopropilamida | |
BRPI0811557A2 (pt) | composto, composição farmacêutica, método de tratamento ou profilaxia de uma condição inflamatória. | |
TW200734335A (en) | Compounds | |
MA32512B1 (fr) | Derive de phenanthrenone, compositions et procedes | |
WO2011046905A3 (fr) | Compositions pharmaceutiques | |
BR112012011261A2 (pt) | tratamento de infecções microbianas | |
UA103626C2 (en) | Dioxabicyclo[3,2,1]octane-2,3,4-triol derivatives | |
UA103416C2 (en) | Normal;heading 1;heading 2;heading 3;DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES |